448 related articles for article (PubMed ID: 17114205)
1. Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta.
Aström E; Jorulf H; Söderhäll S
Arch Dis Child; 2007 Apr; 92(4):332-8. PubMed ID: 17114205
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta.
Aström E; Söderhäll S
Arch Dis Child; 2002 May; 86(5):356-64. PubMed ID: 11970931
[TBL] [Abstract][Full Text] [Related]
3. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up in osteogenesis imperfecta type VI.
Trejo P; Palomo T; Montpetit K; Fassier F; Sato A; Glorieux FH; Rauch F
Osteoporos Int; 2017 Oct; 28(10):2975-2983. PubMed ID: 28689307
[TBL] [Abstract][Full Text] [Related]
5. Cyclic pamidronate therapy in children with osteogenesis imperfecta.
Salehpour S; Tavakkoli S
J Pediatr Endocrinol Metab; 2010; 23(1-2):73-80. PubMed ID: 20432809
[TBL] [Abstract][Full Text] [Related]
6. Bone densitometry in pediatric patients treated with pamidronate.
Grissom LE; Kecskemethy HH; Bachrach SJ; McKay C; Harcke HT
Pediatr Radiol; 2005 May; 35(5):511-7. PubMed ID: 15655696
[TBL] [Abstract][Full Text] [Related]
7. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment.
Land C; Rauch F; Munns CF; Sahebjam S; Glorieux FH
Bone; 2006 Oct; 39(4):901-6. PubMed ID: 16730480
[TBL] [Abstract][Full Text] [Related]
8. Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age.
Alcausin MB; Briody J; Pacey V; Ault J; McQuade M; Bridge C; Engelbert RH; Sillence DO; Munns CF
Horm Res Paediatr; 2013; 79(6):333-40. PubMed ID: 23735642
[TBL] [Abstract][Full Text] [Related]
9. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
Glorieux FH; Bishop NJ; Plotkin H; Chabot G; Lanoue G; Travers R
N Engl J Med; 1998 Oct; 339(14):947-52. PubMed ID: 9753709
[TBL] [Abstract][Full Text] [Related]
10. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
Land C; Rauch F; Travers R; Glorieux FH
Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
[TBL] [Abstract][Full Text] [Related]
11. New trends in the treatment of osteogenesis imperfecta type III - own experience.
Jakubowska-Pietkiewicz E; Chlebna-Sokół D
Ortop Traumatol Rehabil; 2008; 10(6):593-601. PubMed ID: 19153548
[TBL] [Abstract][Full Text] [Related]
12. Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta.
Atta I; Iqbal F; Lone SW; Ibrahim M; Khan YN; Raza J
J Coll Physicians Surg Pak; 2014 Sep; 24(9):653-7. PubMed ID: 25233970
[TBL] [Abstract][Full Text] [Related]
13. Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy.
Arikoski P; Silverwood B; Tillmann V; Bishop NJ
Bone; 2004 Mar; 34(3):539-46. PubMed ID: 15003801
[TBL] [Abstract][Full Text] [Related]
14. Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta.
Aström E; Söderhäll S
Acta Paediatr; 1998 Jan; 87(1):64-8. PubMed ID: 9510450
[TBL] [Abstract][Full Text] [Related]
15. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate.
Lindahl K; Kindmark A; Rubin CJ; Malmgren B; Grigelioniene G; Söderhäll S; Ljunggren Ö; Åström E
Bone; 2016 Jun; 87():11-8. PubMed ID: 26957348
[TBL] [Abstract][Full Text] [Related]
16. Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta.
Löwing K; Aström E; Oscarsson KA; Söderhäll S; Eliasson AC
Acta Paediatr; 2007 Aug; 96(8):1180-3. PubMed ID: 17578486
[TBL] [Abstract][Full Text] [Related]
17. Pamidronate treatment of less severe forms of osteogenesis imperfecta in children.
Zacharin M; Kanumakala S
J Pediatr Endocrinol Metab; 2004 Nov; 17(11):1511-7. PubMed ID: 15570988
[TBL] [Abstract][Full Text] [Related]
18. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate.
Munns CF; Rauch F; Zeitlin L; Fassier F; Glorieux FH
J Bone Miner Res; 2004 Nov; 19(11):1779-86. PubMed ID: 15476577
[TBL] [Abstract][Full Text] [Related]
19. Low-dose intravenous pamidronate treatment in osteogenesis imperfecta.
Gökşen D; Coker M; Darcan S; Köse T; Kara S
Turk J Pediatr; 2006; 48(2):124-9. PubMed ID: 16848111
[TBL] [Abstract][Full Text] [Related]
20. Pamidronate treatment of children with moderate-to-severe osteogenesis imperfecta: a note of caution.
Alharbi M; Pinto G; Finidori G; Souberbielle JC; Guillou F; Gaubicher S; Le Merrer M; Polak M
Horm Res; 2009 Jan; 71(1):38-44. PubMed ID: 19039235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
